Invictus744

Invictus744

📌 Insmed ( NASDAQ:INSM ) – Breakout Opportunity Insmed is a clinical-stage biopharmaceutical company focused on serious and rare lung diseases. The stock more than doubled in May 2024 following positive Phase 3 results for its drug Brensocatib. The FDA has granted Priority Review, with a PDUFA date set for August 12, 2025 — and commercial launch expected in...

Invictus744

Anavex Life Sciences ( NASDAQ:AVXL ) is a clinical-stage biotech developing precision medicine therapies for CNS diseases like Alzheimer’s, Rett syndrome, and Parkinson’s. Its lead drug has shown promising Phase IIb/III data in Alzheimer’s. The company holds strong IP, operates debt-free, and benefits from long-term tailwinds in neurodegenerative treatment...

Invictus744

United States Antimony Corporation UAMY is the only significant U.S.-based producer of antimony, a critical mineral used in flame retardants, batteries, semiconductors, and military applications. The company controls mining, refining, and sales, positioning itself to benefit from growing domestic demand and geopolitical supply risks as China dominates over 80...